

# **BLUDIGO- indigotindisulfonate sodium injection**

## **Provepharm Inc.**

-----

### **HIGHLIGHTS OF PRESCRIBING INFORMATION**

**These highlights do not include all the information needed to use BLUDIGO safely and effectively. See full prescribing information for BLUDIGO.**

**BLUDIGO® (indigotindisulfonate sodium injection), for intravenous use**  
**Initial U.S. Approval: 2022**

### ----- **INDICATIONS AND USAGE** -----

BLUDIGO is a diagnostic dye indicated for use as a visualization aid in the cystoscopic assessment of the integrity of the ureters in adults following urological and gynecological open, robotic, or endoscopic surgical procedures. (1)

### ----- **DOSAGE AND ADMINISTRATION** -----

- Recommended dose is 5 mL given intravenously over 1 minute. (2.1)
- Monitor blood pressure and heart rhythm during and after injection. (2.2)

### ----- **DOSAGE FORMS AND STRENGTHS** -----

Injection: 40 mg/5 mL (8 mg/mL) indigotindisulfonate sodium in a single-dose ampule (3)

### ----- **CONTRAINDICATIONS** -----

- Known hypersensitivity to indigotindisulfonate or any of its components. (4)

### ----- **WARNINGS AND PRECAUTIONS** -----

- Cardiovascular Reactions: Severe or life-threatening cardiovascular reactions including cardiac arrest, arrhythmia, asystole, atrioventricular block second degree, hypotension, elevation in blood pressure, bradycardia, and tachycardia have been reported. Closely monitor blood pressure and cardiac rhythm during and following the BLUDIGO injection. Interrupt administration if reactions are observed. (5.1)
- Hypersensitivity Reactions: Serious anaphylactic reactions with hypotension, dyspnea, bronchospasm, urticaria, or erythema have been reported. Monitor patients for anaphylactic reactions and have emergency equipment and trained personnel readily available. (5.2)
- Interference with Oximetry Measurements: Anesthesiologists should be aware of the potential for artifactual reduction in SpO<sub>2</sub> when anesthetized patients are administered BLUDIGO. (5.3)

### ----- **ADVERSE REACTIONS** -----

Adverse reactions (≥ 1%) are constipation, nausea, vomiting, abdominal pain, pyrexia, ALT increase, and dysuria. (6.1)

**To report SUSPECTED ADVERSE REACTIONS, contact PROVEPHARM Inc at 1-833-727-6556 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

### ----- **USE IN SPECIFIC POPULATIONS** -----

- Renal Impairment: BLUDIGO is not recommended for use in patients with eGFR<30 mL/min. (8.6)

**See 17 for PATIENT COUNSELING INFORMATION.**

**Revised: 11/2022**

---

## **FULL PRESCRIBING INFORMATION: CONTENTS\***

### **1 INDICATIONS AND USAGE**

### **2 DOSAGE AND ADMINISTRATION**

2.1 Recommended Dosage

2.2 Important Administration Instructions

### **3 DOSAGE FORMS AND STRENGTHS**

### **4 CONTRAINDICATIONS**

### **5 WARNINGS AND PRECAUTIONS**

- 5.1 Cardiovascular Reactions
- 5.2 Hypersensitivity Reactions
- 5.3 Interference with Oximetry Measurements

### **6 ADVERSE REACTIONS**

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

### **8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment

### **11 DESCRIPTION**

### **12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

### **13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

### **14 CLINICAL STUDIES**

### **16 HOW SUPPLIED/STORAGE AND HANDLING**

### **17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

---

## **FULL PRESCRIBING INFORMATION**

### **1 INDICATIONS AND USAGE**

BLUDIGO is indicated for use as a visualization aid in the cystoscopic assessment of the integrity of the ureters in adults following urological and gynecological open, robotic, or endoscopic surgical procedures.

### **2 DOSAGE AND ADMINISTRATION**

#### **2.1 Recommended Dosage**

The recommended dose of BLUDIGO is 5 mL given as an intravenous injection over 1 minute.

The blue color is detectable at the ureteral orifices within 4 minutes to 9 minutes after the intravenous injection.

#### **2.2 Important Administration Instructions**

- Monitor blood pressure and cardiac rhythm during and following the injection [see

*Warnings and Precautions (5.1)].*

- Use immediately after opening ampule.
- Withdraw the contents of the ampule through a 5 micron or smaller filter straw/filter needle to ensure that the withdrawn solution contains no particulates. The withdrawn solution should be inspected visually for particulate matter and discoloration prior to administration.
- Do not administer with infusion assemblies used with other diluents or drugs.
- Discard any unused portion.

### **3 DOSAGE FORMS AND STRENGTHS**

Injection: 40 mg/5 mL (8 mg/mL) indigotindisulfonate sodium as a dark blue or bluish-purple solution in a single-dose amber glass ampule.

### **4 CONTRAINDICATIONS**

BLUDIGO is contraindicated in patients with known hypersensitivity to indigotindisulfonate or any of its components [*see Warnings and Precautions (5.2)].*

### **5 WARNINGS AND PRECAUTIONS**

#### **5.1 Cardiovascular Reactions**

Severe or life-threatening cardiovascular reactions including cardiac arrest, arrhythmia, asystole, second degree atrioventricular block, hypotension, elevation in blood pressure, bradycardia, and tachycardia have been reported generally within 60 minutes following administration of indigotindisulfonate sodium injection products and required urgent intervention [*see Adverse Reactions (6.2)].*

Indigotindisulfonate may cause vasoconstriction by interference with vasodilation mediated by nitric oxide dependent mechanisms and by direct vasoconstriction. Indigotindisulfonate may also cause hypotension. Patients with hypertension, heart rate and conduction disorders, or medications causing bradycardia may be at increased risk for elevated blood pressure, hypotension, and bradycardia.

Closely monitor blood pressure and cardiac rhythm during and following the injection of BLUDIGO. Interrupt administration if reactions are observed.

#### **5.2 Hypersensitivity Reactions**

Serious anaphylactic reactions with hypotension, dyspnea, bronchospasm, urticaria, or erythema have been reported with the use of indigotindisulfonate sodium injection products [*see Adverse Reactions (6.2)].* BLUDIGO is contraindicated in patients with known hypersensitivity to indigotindisulfonate [*see Contraindications (4)].* Monitor patients for anaphylactic reactions and have emergency equipment and trained personnel readily available.

#### **5.3 Interference with Oximetry Measurements**

Indigotindisulfonate has been reported to interfere with light absorption and transiently

interfere with pulse oximetric methods. Anesthesiologists should be aware of the potential for artifactual reduction in SpO<sub>2</sub> when anesthetized patients are administered BLUDIGO.

## 6 ADVERSE REACTIONS

Clinically significant adverse reactions are described elsewhere in the labeling:

- Cardiovascular Reactions [see Warnings and Precautions (5.1)]
- Hypersensitivity Reactions [see Warnings and Precautions (5.2)]

### 6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of BLUDIGO was evaluated in a randomized, intra-patient controlled, blind to dose of BLUDIGO, clinical trial. A total of 118 adult patients undergoing endoscopic urological or gynecological procedures were treated intravenously; 58 (49%) of these patients received one dose of BLUDIGO 2.5 mL and 60 (51%) of patients received one dose of BLUDIGO 5 mL. The 2.5 mL dose is not approved [see Dosage and Administration (2.1)]. The mean age of patients was 51 years and 35 (30%) patients were 65 years of age or older. The majority of patients were White 105 (89%) and female 87 (74%).

The adverse reactions ( $\geq 1\%$ ) reported in the clinical trial are provided in Table 1.

**Table 1. Adverse Reactions Reported at  $\geq 1\%$  of Patients Receiving BLUDIGO 5 mL Intravenously**

	BLUDIGO 5 mL (N=60) n (%)
Constipation	3 (5.0)
Nausea	2 (3.3)
Vomiting	2 (3.3)
Abdominal Pain	2 (3.3)
Pyrexia	2 (3.3)
ALT increase	2 (3.3)
Dysuria	1 (1.7)

### 6.2 Postmarketing Experience

The following adverse reactions have been identified following the use of indigotindisulfonate sodium injection products.

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

*Cardiovascular disorders:* cardiac arrest, arrhythmia, asystole, atrioventricular block second degree, hypotension, elevation in blood pressure, bradycardia, tachycardia

*General disorders and administration site conditions:* injection site discoloration

*Immune system disorders:* anaphylactic reactions with hypotension, dyspnea, bronchospasm, urticaria, erythema

## **8 USE IN SPECIFIC POPULATIONS**

### **8.1 Pregnancy**

#### Risk Summary

Available data from case reports, case series, observational studies and clinical experience with indigotindisulfonate sodium injection use in pregnant women over several decades have not identified a drug associated risk of adverse maternal and fetal adverse effects. Indigotindisulfonate sodium injection use during the first trimester of pregnancy is rare; thus, the data are insufficient to evaluate for a drug associated risk of major birth defects and miscarriage. The majority of the published data were from intra-amniotic injections. Animal reproduction studies using the intravenous route of administration have not been conducted. Oral administration of indigotindisulfonate sodium to pregnant rats and rabbits produced no evidence of fetal harm. However, oral availability is low (3%) so that the risk of intravenous administration of indigotindisulfonate sodium during pregnancy cannot be evaluated from the data available .

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

### **8.2 Lactation**

#### Risk Summary

It is not known if indigotindisulfonate is present in animal or human milk. The transfer of indigotindisulfonate into breastmilk is likely to be low and adverse effects on the breastfed infant are not expected [see *Clinical Pharmacology (12.3)*]. There are no data on the effect of indigotindisulfonate on the breastfed infant or milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BLUDIGO and any potential adverse effects on the breastfed infant from BLUDIGO or from the underlying maternal condition.

### **8.4 Pediatric Use**

The safety and effectiveness of BLUDIGO have not been established in pediatric patients.

### **8.5 Geriatric Use**

Of the total number of subjects in the clinical study of BLUDIGO, 23 (20%) were 65 to 74 years of age, and 12 (10%) were 75 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

## 8.6 Renal Impairment

Indigotindisulfonate is known to be excreted by the kidney through tubular secretion. No dedicated pharmacokinetic study using BLUDIGO in patients with varying degree of renal impairment has been conducted. Based on subgroup analyses in the randomized clinical trial, dose adjustment is not needed in patients with mild to moderate renal impairment (estimated glomerular filtration rate (eGFR) 30 to 89 mL/min derived from the Modification of Diet in Renal Disease formula).


BLUDIGO has not been studied in patients with eGFR < 30 mL/min and is not recommended for use in these patients.

## 11 DESCRIPTION

BLUDIGO (indigotindisulfonate sodium injection, USP) is a sterile deep blue or bluish-purple diagnostic dye for intravenous use.

Each mL contains 8 mg indigotindisulfonate sodium (equivalent to 7.2 mg indigotindisulfonate) and may also contain citric acid and sodium citrate to adjust pH value between 3 and 6.5 and has an osmolality  $\leq 0.05$  osmol/kg. Indigotindisulfonate sodium is also known as indigo carmine.

The chemical name of indigotindisulfonate sodium is Disodium 3,3'-dioxo- $[\Delta^{2,2'}$ -biindoline]-5,5'-disulfonate. Its molecular formula is  $C_{16}H_8N_2Na_2O_8S_2$  and its molecular weight is 466.35 g/mol. Its structural formula is:



indigotindisulfonate sodium

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

Indigotindisulfonate is a dye excreted by the kidney through tubular secretion and enhances visualization of the ureteral orifices by its deep blue color.

### 12.2 Pharmacodynamics

The blue color is detectable at the ureteral orifices within 4 minutes to 9 minutes after the intravenous injection.

### 12.3 Pharmacokinetics

The pharmacokinetic properties of BLUDIGO are presented in Table 2.

**Table 2. Pharmacokinetics of Indigotindisulfonate in Healthy Adults Following Intravenous Administration of BLUDIGO 5 mL (40 mg)**

		<b>BLUDIGO</b>
		<b>5 mL (40 mg)</b>
<b>General Information</b>		
C <sub>max</sub> (CV%), µg/mL		6.33 (58.4)
AUC <sub>0-∞</sub> (CV%), µg·h/mL		1.15 (36.4)
<b>Distribution</b>		
Mean (CV%) Volume of Distribution, L		10.7 (36.1)
Protein Binding, in vitro		About 90%
<b>Elimination</b>		
Mean (CV%) Elimination Half-life, minutes		12 (34.1)
Mean (CV%) Clearance, L/hour	Urinary	7.08 (66.3)
	Total	40.2 (45.1)
<i>Metabolism</i>		
Primary Metabolic Pathways		Oxidative metabolism
<i>Excretion</i>		
Urine (CV%) <sup>a</sup>		16.0% (44.0)
Feces		<2%
<sup>a</sup> Unchanged drug C <sub>max</sub> = maximum plasma concentration; AUC <sub>0-∞</sub> =area under the plasma concentration-time curve from time of administration extrapolated to infinity; CV=coefficient of variation		

## 13 NONCLINICAL TOXICOLOGY

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

#### Carcinogenicity

Carcinogenicity studies in animals have not been conducted with indigotindisulfonate sodium using the intravenous route of administration.

Long-term studies in mice with oral and subcutaneous administration of indigotindisulfonate sodium revealed no carcinogenic effects.

#### Mutagenesis

Although indigotindisulfonate sodium has been evaluated in a number of Ames assay studies, an Ames assay study that follows all currently recommended guidelines has not been performed. Indigotindisulfonate was not genotoxic in all those Ames assays. The mutagenicity of indigotindisulfonate was inconclusive in the *in vitro* mouse L5187Y

Lymphoma TK +/- assay. Orally administered indigotindisulfonate was not mutagenic in the *in vivo* mouse micronucleus test. An *in vivo* micronucleus test with indigotindisulfonate sodium using the intravenous route of administration has not been conducted.

#### Fertility

Fertility studies with indigotindisulfonate sodium using the intravenous route of administration have not been conducted.

## **14 CLINICAL STUDIES**

The safety and efficacy of BLUDIGO were evaluated in a randomized intra-patient controlled, blind to dose of BLUDIGO, multi-center study (NCT04228445) in 118 adult patients undergoing endoscopic urological or gynecological surgical procedures including cystoscopic (58%), robotic (28%), and transvaginal (14%) approaches.

The majority of patients were white (89%), female (74%), and younger than 65 years of age (70%). Mean age was 51 years, and age ranged from 20 to 88 years.

Patients were randomized in a 1:1 ratio to receive 2.5 mL or 5 mL of BLUDIGO intravenously prior to the end of the surgical procedure. Each patient underwent cystoscopy and received 5 mL of sodium chloride injection 0.9% followed by the randomized BLUDIGO dose for visualization of urinary flow from the ureteral orifices. The 2.5 mL dose is not approved [see *Dosage and Administration (2.1)*].

The ureteral orifices and urine flow were observed and video recorded from 0 to 10 minutes post injection, with separate recordings made following sodium chloride injection and BLUDIGO. The conspicuity of the urine flow from the ureteral orifices was assessed in a randomized, blinded fashion by two independent central reviewers using a 5-point scale (1 = no urine flow observed; 2 = weak urine flow, little color contrast; 3 = Color contrast or significant urine flow; 4 = strong urine flow with good color contrast; and 5 = strong urine flow with striking contrast in color) once after sodium chloride injection and twice after BLUDIGO resulting in paired data. The surgeons also reviewed and scored conspicuity of the urine flow from the ureteral orifices. The responder for a ureter is defined as the difference in conspicuity score between BLUDIGO and sodium chloride injection being at least one point difference and the conspicuity score following BLUDIGO alone being greater than or equal to three. The reviewer agreement with the responder endpoint is acceptable. The proportion of responders along with its 95% confidence interval by ureter and reviewer or surgeon is summarized in Table 3.

**Table 3. Summary of Proportion of Responders by Ureter and Reviewer or Surgeon in Patients Receiving BLUDIGO 5 mL**

	BLUDIGO 5 mL	
	Left Ureter (n=49)	Right Ureter (n=49)
Reviewer 1 % Responder* 95% CL**	63% (48%, 77%)	76% (61%, 87%)
Reviewer 2 % responder	78% (63%, 88%)	82% (68%, 91%)

95% CL		
Surgeon % responder 95% CL	71% (57%, 83%)	82% (68%, 91%)

\*responder: IC conspicuity score  $\geq 3$  and difference (IC – Saline) in conspicuity score  $\geq 1$ , missing data is imputed as non-responder

\*\* two-sided 95% confidence limits for the proportion of responder, calculated using the Clopper-Pearson (Exact) method

## 16 HOW SUPPLIED/STORAGE AND HANDLING

### How Supplied

BLUDIGO (indigotindisulfonate sodium injection, USP) 40 mg/5 mL (8 mg/mL) is a dark blue or bluish-purple solution supplied in a carton of 5 single-dose amber glass ampules (NDC 81284-315-05).

### Storage and Handling

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

Store in original carton to protect from light.

Do not refrigerate or freeze.

Use immediately after opening ampule. Discard unused portion.

## 17 PATIENT COUNSELING INFORMATION

### Cardiovascular Reactions

Advise the patient of the possibility of developing elevated blood pressure, hypotension, bradycardia, tachycardia, or atrioventricular block during or after the administration of BLUDIGO [see *Warnings and Precautions (5.1)*].

### Injection Site and Urine Discoloration

Inform the patient that BLUDIGO may cause a blue discoloration of injection site and urine and that the discoloration should resolve within 48 hours. Advise the patient to inform the healthcare provider if the discoloration of the injection site is associated with other symptoms [see *Adverse Reactions (6.2)*].

### **Manufactured for:**

PROVEPHARM SAS

13013 Marseille, FRANCE

### **Manufactured by:**

CENEXI

52 rue Marcel et Jacques Gaucher

94120 Fontenay sous Bois, FRANCE

### **Distributed by:**

PROVEPHARM INC.

Collegeville, PA 19426, USA

**PRINCIPAL DISPLAY PANEL - CARTON**

Rx only NDC 81284-**315**-05

**Bludigo®**  
**indigotindisulfonate**  
**sodium Injection, USP**

**5 AMPULES OF 5 ML**

**40 mg/5 mL (8 mg/mL)**

**Intravenous use only**  
**5 mL - Single dose ampule**

**Discard unused portion**

Patented: US 10,927,258; US 11,499,050  
US 11,845,867

**PROVEPHARM**

**Bludigo**<sup>®</sup>  
indigotindisulfonate  
sodium Injection, USP  
40 mg/5 mL (8 mg/mL)

Rx only

NDC 81284-315-05

**Bludigo**<sup>®</sup>  
indigotindisulfonate  
sodium Injection, USP

5 AMPULES OF 5 ML

5 AMPULES OF 5 ML  
**PROVEPHARM**

**40 mg/5 mL (8 mg/mL)**

**Intravenous use only**  
**5 mL - Single dose ampule**  
**Discard unused portion**

**PROVEPHARM**

Patented: US 10,927,258; US 11,499,050  
US 11,845,867

28069224

**Manufactured by:**  
CENEXI  
52 rue Marcel et Jacques Gaucher  
94120 Fontenay sous Bois  
France

**PROVEPHARM**



Rev. 02/2024

Bludigo is a registered trademark of Provepharm.

**Manufactured by CENEXI for:**  
**Provepharm SAS**  
Marseille, France

**Distributed by:**  
**Provepharm, Inc.**  
Collegeville, PA

**For single dose only.**  
Any solution remaining in the opened ampules must be discarded.

**Intravenous use only.**  
Recommended Dosage: See Prescribing Information.  
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) in the carton to protect from light.  
Do not refrigerate or freeze.

Each mL contains 8 mg indigotindisulfonate sodium (equivalent to 7.2 mg indigotindisulfonate) and may also contain citric acid and sodium citrate to adjust pH value between 3 and 6.5 and has an osmolality ≤ 0.05 osmol/kg.

(01) 00381284315050

GTIN  
EXP  
Lot  
S/N

**Bludigo**<sup>®</sup>  
indigotindisulfonate  
sodium Injection, USP

**40 mg/5 mL (8 mg/mL)**

5 AMPULES OF 5 ML

**PROVEPHARM**



**PRINCIPAL DISPLAY PANEL - VIAL**

NDC 81284-315-00 Rev\_12/2022

**Bludigo<sup>®</sup>**  
**indigotindisulfonate sodium**  
**Injection, USP**

**40 mg/5 mL (8 mg/mL)**

Intravenous use only

Single dose ampule

Rx only

Discard unused portion

Manufactured by Cenexi  
for: Provepharm SAS

Distributed by:  
Provepharm, Inc.

28069319

NDC 81284-315-00 Rev\_12/2022

**Bludigo<sup>®</sup>**  
**indigotindisulfonate sodium**  
**Injection, USP**

**40 mg/5 mL (8 mg/mL)**

Intravenous use only  
Single dose ampule  
Rx only  
Discard unused portion

Manufactured by Cenexi  
for: Provepharm SAS


Distributed by:  
Provepharm, Inc. 28069319



(01)00381284315005

Lot

EXP



**BLUDIGO**

indigotindisulfonate sodium injection

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:81284-315
<b>Route of Administration</b>	INTRAVENOUS		

### Active Ingredient/Active Moiety

<b>Ingredient Name</b>	<b>Basis of Strength</b>	<b>Strength</b>
<b>INDIGOTINDISULFONATE SODIUM</b> (UNII: D3741U8K7L) (INDIGOTINDISULFONIC ACID - UNII:X70I7JF73P)	INDIGOTINDISULFONATE SODIUM	8 mg in 1 mL

### Inactive Ingredients

<b>Ingredient Name</b>	<b>Strength</b>
<b>CITRIC ACID MONOHYDRATE</b> (UNII: 2968PHW8QP)	
<b>SODIUM CITRATE</b> (UNII: 1Q73Q2JULR)	

### Packaging

#	<b>Item Code</b>	<b>Package Description</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>
1	NDC:81284-315-05	5 in 1 CARTON	09/06/2022	
1	NDC:81284-315-00	5 mL in 1 AMPULE; Type 0: Not a Combination Product		

### Marketing Information

<b>Marketing Category</b>	<b>Application Number or Monograph Citation</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>
NDA	NDA216264	09/06/2022	

**Labeler** - Provepharm Inc. (086861066)

### Establishment

<b>Name</b>	<b>Address</b>	<b>ID/FEI</b>	<b>Business Operations</b>
CENEXI		573309239	manufacture(81284-315) , pack(81284-315) , analysis(81284-315)

Revised: 11/2025

Provepharm Inc.